Anemia management in ckd
-
Upload
salwa-ibrahim -
Category
Health & Medicine
-
view
309 -
download
3
Transcript of Anemia management in ckd
![Page 1: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/1.jpg)
Anemia management in CKD
Salwa Ibrahim, MD FRCP (Edin)Cairo University
4th CKD course, 15-17 May 2016
![Page 2: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/2.jpg)
Agenda
• Mechanism of anemia
• Hemoglobin Target
• KDIGO guidelines
![Page 3: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/3.jpg)
Introduction
• Anemia was first linked to CKD over 170 years ago by Richard Bright
• Caused primarily by erythropoietin deficiency secondary to renal mass loss
• EPO level is inappropriately low relative to the degree of anemia
![Page 4: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/4.jpg)
Prevalence of anemia severity stratified by stage of chronic kidney disease
![Page 5: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/5.jpg)
Erythropoeisis
• Erythropoeitin (EPO) is a glycoprotein hormone secreted (90%) from endothelial cells in proximity to renal tubules
• EPO stimulates stem cells in the bone marrow to RBC production
• Iron essential in latter phase as Hb incorporated into reticulocytes and released into circulation as RBCs– 2/3rds of iron in the body is in Hb
![Page 6: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/6.jpg)
Mechanism of anemia in CKD
• EPO deficiency
• Iron deficiency
• Uremia induced inhibition
• Shortened RBCs survival
• Nutritional deficiency (folate, B12)
![Page 7: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/7.jpg)
Iron deficiency
• CKD patients have increased iron losses, estimated at 1-3 g per year in hemodialysis patients
• Causes include:
1. Chronic bleeding from uremia-associated platelet dysfunction
2. Frequent phlebotomy
3. Blood trapping in dialysis apparatus
4. Impaired dietary iron absorption (anorexia, use of phosphate binders, PPI and H2 blockers)
![Page 8: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/8.jpg)
Functional iron deficiency
• Impaired iron release from body stores (reticuloendothelial cell iron blockade)
• Hepcidin excess accounts for impaired dietary iron absorption and reticuloendothelial cell iron blockade
• Hepcidin produced by the liver binds and induces degradation of iron exporter (ferroportin) on duodenal enterocytes, reticuloendothelial macrophages, and hepatocytes to inhibit iron entry into plasma
![Page 9: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/9.jpg)
![Page 10: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/10.jpg)
Symptoms of anemia
• Fatigue
• Shortness of breath • Diminished quality of life
• Palpitation
![Page 11: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/11.jpg)
Hazards of anemia in CKD
• LVH, CHF
• IHD
• Impaired immune system
• Diminished cognitive functions
• Progression of CKD
![Page 12: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/12.jpg)
![Page 13: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/13.jpg)
![Page 14: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/14.jpg)
Diagnosis of anemia
![Page 15: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/15.jpg)
![Page 16: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/16.jpg)
![Page 17: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/17.jpg)
Use of ESAs to treat anemia in CKD
![Page 18: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/18.jpg)
ESA MAINTENANCE THERAPY
![Page 19: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/19.jpg)
ESA DOSING
![Page 20: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/20.jpg)
ESA ADMINISTRATION
![Page 21: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/21.jpg)
![Page 22: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/22.jpg)
HCT and Mortality in D-CKD
1.33
1.121.00 0.96
1.251.11
1.00 0.97
0
0.2
0.4
0.6
0.8
1
1.2
1.4
<27% 27% to < 30% 30% to < 33% 33% to < 36%
Hct
All-cause deathCardiac-related death
![Page 23: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/23.jpg)
![Page 24: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/24.jpg)
![Page 25: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/25.jpg)
Largest Studies on Target Hgb in D-CKD
1. Normal Hematocrit Study ≈ 1233 pts (1265)• Besareb et al NEJM 1998
![Page 26: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/26.jpg)
Normal Hematocrit Study
P<0.001*
![Page 27: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/27.jpg)
Largest Studies on Target Hgb ND-CKD
1. The CREATE = 603 pts– Drueke et al NEJM 2006
2. The CHOIR study = 1432 pts– Singh et al NEJM 2006
![Page 28: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/28.jpg)
![Page 29: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/29.jpg)
CHOIR1432 patients, 130 centers, US only
Epoetin-alfa
Randomization
High target Hb(13.5 g/dl)
n=715312 completed 36 mo
or withdrew at study termination with no primary event
125 primary event278 Withdrew before
early termination of study
Required RRT (47.1%)Withdrew for Other Reasons (21%)
Low target Hb(11.3 g/dl)
n=717349 completed 36 mo
or withdrew at study termination with no primary event
97 primary event278 Withdrew before
early termination of study
Required RRT (41.0%)Withdrew for Other Reasons (22%)
Median f/u 16 months
![Page 30: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/30.jpg)
Endpoints
Primary Endpoint: Composite event consist of • Death• Myocardial infarction• Stroke• CHF hospitalization (excluding RRT)
Singh et al,New Engl J Med 2006; 355:2085-98
![Page 31: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/31.jpg)
![Page 32: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/32.jpg)
Summary (CHOIR)
• Increased risk with targeting Hb to 13.5 g/dL and achieving 12.6 g/dL (34% P=0.03)
• Strong trends for Death (48% P=0.07) and CHF Hospitalization (41% P=0.07)
• Higher rate of Cardiovascular (23% P=0.03) and All Hospitalization (18% P 0.03)
• No Incremental QOL of benefit with higher Hb
Singh et al,New Engl J Med 2006; 355:2085-98
![Page 33: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/33.jpg)
![Page 34: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/34.jpg)
![Page 35: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/35.jpg)
(10.5 to 11.5 g per deciliter, group 2)
![Page 36: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/36.jpg)
Summary (CREATE)• Increased risk with targeting higher Hb HR=0.78
• Improvement in QOL in both groups
• No benefit in LVH in the Group 1 with higher hemoglobin
![Page 37: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/37.jpg)
TREAT Study 2009 • The risk of stroke doubled in higher HB group
• The risk of cancer also increased with highr hemoglobin level
![Page 38: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/38.jpg)
Phrommintikul et al al, Lancet 2007
![Page 39: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/39.jpg)
![Page 40: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/40.jpg)
![Page 41: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/41.jpg)
![Page 42: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/42.jpg)
ESA available in Egypt
![Page 43: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/43.jpg)
Eprex (Epoeitin alpha)
– IV or SC– 3 x wk– Most HD pts on this– Initial dose 200-3000 units thrice weekly– Half life 4-11 h IV and 19-25 h SC
![Page 44: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/44.jpg)
Recormon (Epoeitin beta)
• IV or SC
![Page 45: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/45.jpg)
Aranesp (Darbepoeitin)
– IV or SC – extra carbohydrate chain, 3 x longer half life, hence can be
given weekly or fortnightly (non-dialysing pts)– Initial dose 25 mcg weekly to 60 mcg twice monthly
![Page 46: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/46.jpg)
• Methoxy polyethylene glycol-epoetin beta is the active ingredient of a drug marketed by Roche under the brand name Mircera
• Mircera is a long-acting erythropoietin receptor activator (CERA) indicated for the treatment of patients with anemia associated with CKD usually given once monthly (150 mcg)
• The drug stimulates erythropoiesis by interacting with the erythropoietin receptor on progenitor cells in the bone marrow
![Page 47: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/47.jpg)
• It has a different receptor binding activity to other ESAs and its reduced affinity for the erythropoietin receptor allows continuous stimulation
• It has an in vivo half-life of around 135 hours as compared to darbapoietin alfa which has a half life of around 21 hours, the half life of which is three times that of the naturally occurring erythropoietin in the body
• Mircera is supplied as a solution in pre-filled syringes for intravenous or subcutaneous administration
![Page 48: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/48.jpg)
Causes of EPO not working
• Iron deficiency ** most common **• B12 & Folate deficiency• Inflammation• ACE inhibitors• Hyperparathyroidism – bone marrow fibrosis• Aluminium toxicity• Inadequate dialysis• Malignancies, including multiple myeloma
![Page 49: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/49.jpg)
New class of ESA
• Hematinide ( synthetic peptide)
• HIF stabilizer (oral agent) used to stabilize HIF to increase the transcription of EPO
![Page 50: Anemia management in ckd](https://reader036.fdocuments.net/reader036/viewer/2022081420/5879b41d1a28ab6b2c8b63a3/html5/thumbnails/50.jpg)